10X Genomics, Inc. (TXG)
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
$74.39+6.10%
Close 2026-09-15 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-14
Research Workspace
Put TXG beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRevenue is contracting — down about 4% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 117% growth a year, above the roughly 8% analysts expect, leaving little room for error.
View ValuationThis stock is volatile — it swings about 3% on a typical day and fell roughly 28% in its worst 12-month stretch.
View Risk10X Genomics must continue to grow its revenue to justify its current valuation. Revenue grew 3% year over year, and the last quarter beat expectations. It trades at 14.5× price-to-sales, which is significantly above the peer median of 1.8×. The market is pricing in more growth than forecasted, indicating expectations look full. A specific risk is the potential credibility hit if TXG cuts guidance after recently raising it. Peer multiples imply a price about 112% below where it trades (it looks expensive on this basis). This read is provisional.
Trailing returns as of 2026-09-15. TXG is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 18 analysts currently covering TXG (as of Sep 2026).
Based on 9 Wall Street analysts offering 12-month price targets for TXG in the last 4 months.
Continue this research
Compare TXG with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| TXG Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 4 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Technology — fair value, gap to price, and forward P/E.
Compare the value case
Put TXG next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Patent win strengthens competitive position and supports revenue growth.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-15. EPS is implied from price ÷ P/E. Not investment advice.
Current $74.39
The last 12 months of price, then the range of analyst 12-month targets from today’s $74.39.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Launch and commercialize Atera platform
Atera's delivery is crucial for growth and revenue guidance.
Advances: Launch and commercialize Atera platform
Strong early orders confirm Atera platform's market potential.
Advances: Maintain and raise 2026 revenue guidance
2026 outlook lift supports revenue growth expectations.
Advances: Maintain and raise 2026 revenue guidance
Earnings call provides insights into revenue growth trajectory.
Advances: Launch and commercialize Atera platform
Positive sentiment on Atera rollout aligns with product objectives.
Advances: Maintain and raise 2026 revenue guidance
Prepared remarks provide clarity on revenue guidance.
CEO selling shares raises concerns about confidence.